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Placental formation  
Humans have haemochorial placentation in which the placenta is in direct contact with circulating 
maternal blood. The placenta comprises fetal vasculature, stroma, immune cells and cytotrophoblast 
which are extravillous and villous. During implantation, the maternal decidual arteries are invaded 
by placental extravillous cytotrophoblasst resulting in the subsequent remodelling of the decidual 
spiral arteries. During this process, placental extravillous cytotrophoblasts replace maternal 
endothelial cells and disorganise the vascular smooth muscle cells (VSMC). This leads to a high flow 
and low resistance placental circulation enabling effective exchange of nutrients across the chorionic 
villi. The chorionic villi are covered in syncytiotrophoblasts, which are formed from a villous 
cytotrophoblast layer, in direct contact with the maternal blood, and thus trophoblasts, rather than 
the endothelium, form the exchange surface in the intervillous space and act as the gatekeeper 
between maternal blood and embryonic tissues. 
During implantation, tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) play a key role in 
creating a haemostatic envelope around the invading blastocyst thus preventing local decidual 
haemorrhage [1-3]. Unlike other vascular beds, trophoblasts constitutively express TF. In normal 
pregnancies TF procoagulant activity is held in check as the syncytiotrophoblast adapts a 
pseudoendothelial phenotype through the expression of integrin αv/β3, PECAM-1 and E-cadherin 
[4], endothelial protein C receptor (EPCR), thrombomodulin, annexin-V and the tissue factor 
pathway inhibitors (TFPI-1 and TFPI-2). This prevents TF induced thrombin generation in healthy 
pregnancies [5]. TF is essential for fetal and placental development and the prevention of placental 
abruption in later pregnancy, as demonstrated by fetal lethality in TF knockout mice and supported 
by the absence of reported deficiency states in humans [2].  
The protease activated receptors PAR-1, PAR-2 and PAR-3 are also expressed on extravillous 
trophoblasts (EVT) and syncytiotrophoblasts [6, 7] and mediate cytotrophoblast invasion via 
thrombin (PAR-1 and PAR-3) and TF/FVIIa or TF/FXa (PAR-2) activation, whilst PAR-1 simultaneously 
induces differentiation through nuclear recruitment of β -catenin and induction of Wnt-dependent 
T-cell factor 4 [6, 8, 9].  
 
Pre-eclampsia 
Pre-eclampsia (PE) is a disorder of new onset hypertension and proteinuria, thrombocytopenia, 
renal insufficiency or impaired liver function in the second half of pregnancy [10]. The origins of PE 
lie in the placenta, and delivery remains the only effective treatment. PE is a complex syndrome 
with several overlapping subtypes, e.g. early onset or late onset, with or without fetal 
growth restriction (FGR) [11]. PE has been described as a two stage disease [12] with a first 
(pre-clinical) stage comprising deficient remodelling of the uteroplacental spiral arteries (8–
18 weeks), dysfunctional perfusion and placental oxidative stress leading to the clinical 
stage (after 20 weeks) characterised by maternal systemic inflammation and vascular 
dysfunction. While this is undoubtedly true for early onset disease (<34 weeks gestation), 
many cases of late onset PE have no antecedent placental pathology [13] and appear as two 
distinct phenotypes as indicated by the placental histology. In general, placentae from early 
onset PE are smaller than aged matched controls [14],with more infarction and are less well 
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developed, with reduced terminal villi volume and surface area [15, 16]. In contrast, late 
onset PE placentas are frequently larger with similar morphology to normal term placentas 
and some show increased arteriopathy [16].  
The diverse nature of PE is also reflected by the maternal haemodynamic state. Early onset 
PE and, to a lesser extent, normotensive FGR are preceded by increased total vascular 
resistance and low cardiac output, where as those women destined to develop late onset PE 
are characterised by low total vascular resistance and high cardiac output [17]. This has led 
to the concept of “placental PE” in which an abnormal placenta interacts with normal 
maternal vasculature leading to early onset disease, and “maternal PE” in which a normal 
placenta interacts with abnormal vasculature to produce late onset disease [18]. Although 
the aetiology of the different subtypes is clearly distinct, the maternal syndrome of 
hypertension, proteinuria and oedema due as a result of vascular inflammation and 
endothelial dysfunction represent a common pathway. This is driven by increased placental 
release of the soluble isoforms of the vascular endothelial growth factor receptor 1 
(sVEGFR1 or sFlt-1) and endoglin (soluble TGFβ-1 receptor) with reduced placental growth 
factor (PlGF) [18].  
Perhaps unsurprisingly, given the heterogeneous nature of the condition, many pathogenic 
mechanisms have been proposed and these have been recently reviewed [19].This review 
will concentrate on haemostatic mechanisms responsible for placental dysfunction.  
As previously discussed, tissue factor is essential for placental development. PAR signalling is 
important in trophoblast differentiation and a failure of trophoblasts to adopt an 
endothelial phenotype is associated with PE [4]. However, increased TF expression 
[2](Girardi, 2010) and/or exposure of trophoblast TF to FVIIa during decidual haemorrhage 
causes inappropriate activation of the coagulation cascade and this has been proposed as 
the primary cause of impaired trophoblast invasion of the decidua (Lockwood et al., 2011). 
Increased expression of TF in endothelium of the basal decidua is associated with bilateral 
notching of the uterine artery and severe PE with FGR [20]. Aberrant syncytiotrophoblast TF 
expression has been reported in PE [21, 22] with a corresponding reduction in TFPI1 [21] 
and TFPI2 [23, 24]. We have also demonstrated increased tissue factor activity on 
syncytiotrophoblast extracellular vesicles (STEV) released into the maternal circulation from 
the placenta in PE [25].  
Over expression of villous trophoblast PAR-1 is also a feature of early onset preeclampsia 
[26]. Excessive thrombin activation of PAR-1 enhances sflt-1 expression and secretion by 
trophoblasts through the PAR-1 /NADPH oxidase /ROS signalling pathway [27, 28](Zhao et 
al., 2012, Huang et al., 2015). This is evinced by increased maternal markers of in vivo 
thrombin generation and fibrin turnover [29-32]. This represents a clear link between 
increased placental TF and the resultant thrombin activation of PAR-1 [33] leading to excess 
sflt-1 secretion and maternal endothelial dysfunction. Perhaps of more importance to the 
foetus is the localised effect of thrombin generation in the placenta. Perivillous fibrin 
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deposition and placental infarction are strongly associated with early onset PE and severe 
disease [34] [35-37].  
Infarction may lead to localised hypoxia and the expression of hypoxia-inducible factor 1-
alpha (HIF-1α). Several studies have shown that women with PE have persistently elevated 
placental HIF-1α which promotes enhanced transcription of genes encoding sFlt-1, endoglin 
and endothelin-1, all of which are known to contribute to preeclampsia [38-40]. Moreover, 
expression of HIF-1α is upregulated not only by hypoxia, but also by inflammatory stimuli 
(for example, thrombin, vasoactive peptides, cytokines, such as TNFα, and reactive oxygen 
species [ROS]), especially those mediated by NF-κB, as the promoter of HIF-1α contains an 
NF-κB binding site [19].  
 
 
Changes in systemic maternal haemostasis  
Normal pregnancy is associated with a physiological increase in many procoagulant factors and 
inhibitors of fibrinolysis. Increases in coagulation factors VII, VIII, X, XII and XIII, fibrinogen and von 
Willebrand factor are all commonly observed and are maximal around term. Free protein S 
decreases throughout pregnancy and this is reflected by increasing resistance to activated protein C 
(APC). Fibrinolytic activity is reduced during pregnancy, as a result of increased levels of plasminogen 
activator inhibitor-1 (PAI-1) from endothelial cells and plasminogen activator inhibitor-2 (PAI-2) from 
the placenta [41]. These changes are necessary in order to meet the haemostatic challenge of 
parturition but contribute to an increased risk of venous thromboembolism during pregnancy and 
the puerperium. A benign gestational thrombocytopenia is not infrequently observed, particularly in 
the third trimester but this is not associated with excessive platelet activation and is most probably 
due to increased plasma volume. As might be expected, markers of in vivo thrombin generation 
(thrombin-antithrombin complexes [TAT] and prothrombin fragment 1.2 [PF1.2]) are slightly 
increased as is the endogenous thrombin potential (ETP) assay [42].  
The association between coagulation activation and preeclampsia has been recognised since the 
early 1950s. The shift in the haemostatic balance towards a procoagulant/hyperfibrinolytic picture 
observed in normal pregnancy is exaggerated in preeclampsia. Many consider the haemostatic 
changes observed in mild preeclampsia as an augmentation of the normal maternal physiological 
response. This is in contrast to severe preeclampsia in which the imbalance of the haemostatic 
system is pathological, reflecting the systemic inflammation and endothelial dysfunction 
characteristic of the disease. In practice, a spectrum of haemostatic changes are observed; from the 
subtle variations seen in mild preeclampsia to the unregulated disseminated intravascular 
coagulation (DIC) observed in the HELLP (haemolysis, elevated liver enzymes and low platelets) 
syndrome. Increased thrombomodulin activity, tissue factor activity and procoagulant phospholipids 
are observed [43, 44].  
The role of platelets 
The association of excessive platelet activation and consumption in PE has been recognised for many 
years [45, 46]. There is now ample evidence to implicate platelet activation in the pathogenesis of 
PE. Platelet activation may occur several weeks prior to the onset of symptomatic PE [47, 48]; 
Increased mean platelet volume in late first trimester of pregnancy has been reported to predict 
intrauterine growth restriction and PE [49]; Platelet-derived soluble factors are reported to regulate 
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human extravillous trophoblast differentiation and invasion into maternal spiral arteries [50]; Low 
dose aspirin (LDA) initiated before the 16th week of gestation significantly reduces the incidence and 
severity of preeclampsia, FGR and preterm birth, whereas LDA initiated after the 16th week has little 
effect on pregnancy outcome [51]; Increased platelet-leucocyte aggregates are observed in PE 
compared to normotensive pregnancies [44, 52] and these have been identified as a significant 
source of extraplacental sflt-1 in women with PE during pregnancy and for several months post-
partum [53, 54].  
We have demonstrated that platelets take up extracellular vesicles derived from the 
syncytiotrophoblast (STEVs) in vitro [55, 56] and that placenta-specific proteins and mRNA are 
detectable in platelets isolated from the peripheral blood of pregnant women. Furthermore, 
incubation of platelets with STEV leads to platelet degranulation in vitro (unpublished data). This is 
consistent with previous reports of reduced aggregation response to weak agonists in platelets from 
PE women due to “exhausted” platelets [57-60]. It is possible that systemic release of vasoactive 
substances by platelets during PE may contribute to vascular dysfunction. Most recently, it has been 
shown that endothelial EVs cause the accumulation of activated platelets within the placental 
vascular bed leading to inflammasome activation in trophoblasts in a mouse model of PE [61]. 
 
The role of neutrophils 
Normal pregnancy is characterized by the presence of innate immune cells at the feto-maternal 
interface from the first trimester. It has been proposed that TLR stimulated trophoblasts recruit 
neutrophils via the release of IL-8 [62]. IL-8 and STEV released from placental explants induce the 
formation of neutrophil extracellular traps (NETs) in vitro [63]. Furthermore NETs have been 
demonstrated in the intervillous space of placentae from pre-eclamptic women and it has been 
proposed that NET formation may be responsible for the increased cell-free DNA observed in the 
plasma of women with PE [64]. As NETs are known to promote thrombosis in a P-selectin-dependent 
manner [65, 66] it is possible that NET formation may contribute to placental infarction.  
In a rat model of PE, neutrophil depletion was shown to attenuate placental ischaemia-associated 
hypertension, suggesting a significant role for neutrophils in the pathogenesis of PE [67]. It has been 
reported that activated endothelial cells induce NET formation which in turn causes further 
endothelial damage [68]. This, and the association of NETs with thrombotic microangiopathies [69], 
suggest a role for systemic NET involvement in fulminating  PE and HELLP syndrome.  
 
Anti-phospholipid antibodies and PE 
Maternal antiphospholipid antibodies (aPL) are associated with recurrent miscarriage, intrauterine 
death, preeclampsia, intrauterine growth restriction and premature birth [70]. For many years, it has 
been assumed that the role of aPL in the pathogenesis obstetric antiphospholipid syndrome (APS) is 
primarily thrombotic. However, recent findings question the validity of this assumption. Combined 
LDA and heparin are effective in improving pregnancy outcome in women with APS and a history of 
early pregnancy loss [71-73] but women with APS and prior fetal loss remain at high risk of placenta-
mediated complications despite treatment with LDA and LMWH [74].  
 
Heparin appears to exert its protective effect through the inhibition of complement activation [75]. 
aPL cause a complement-independent inflammatory response by signalling through TLR-4 on EVT 
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[76] whereas pregnancies in mice infused with non-complement-fixing β2GP1 single chain antibody 
were unaffected [77]. Furthermore, inhibition of C3 convertase prevented fetal loss and growth 
retardation in mice injected with human aPL [78]. A recent clinical trial reported pravastatin 
improved pregnancy outcome in women with APS who were refractory to LMW/LDA and previously 
developed PE [79] 
Conclusions 
It is clear that haemostatic mechanisms play an important role in the pathogenesis of PE. It is hoped 
that our increased knowledge in this field will identify new therapeutic strategies for the treatment 
and prevention of this dangerous condition.  
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Figure legend 
Figure 1. Haemostatic mechanisms in placental insufficiency. Syncytiotrophoblast stress induces TF 
expression and activation of complement factors C3 and C5. This causes neutrophil recruitment, 
activation and oxidative burst. TF positive STBEV bind platelets triggering the release of ADP and 
thrombin generation and. Thrombin activates PAR1 receptors on the Syncytiotrophoblast, platelets 
and neutrophils causing further cellular activation. The resulting syncytiotrophoblast inflammation 
promotes increased shedding of TF STBEV and release of sFlt-1. 
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